Quantification of γδ T cells and HLA-DR+ NK cells does not predict emergence of new contrast enhancing lesions in MS patients suspending natalizumab treatment.
PLoS One
; 12(6): e0179095, 2017.
Article
em En
| MEDLINE
| ID: mdl-28586378
ABSTRACT
BACKGROUND:
Natalizumab (NTZ) is a drug that has been widely used in the treatment of multiple sclerosis (MS). NTZ is very effective in suppressing inflammation, but if treatment is suspended many patients will experience relapses.OBJECTIVE:
To investigate if quantification of γδ T cells and HLA-DR+ NK cells could predict early disease reactivation after NTZ suspension.METHODS:
Absolute counts of γδ T cells and HLA-DR+ NK cells in whole blood were determined with flow cytometry in fifteen patients treated with NTZ. NTZ treatment was then withdrawn and patients were followed with clinical visits and MR investigations.RESULTS:
Patients with recurrent disease had higher absolute counts of γδ T cells 129 (±156) cells/µl in comparison to patients with stable disease 50.0 (±51.0) cells/µl but the difference was not statistically significant and largely driven by outliers. Patients with recurrent and stable disease had similar absolute counts of HLA-DR+ NK cells.CONCLUSION:
Quantification of γδ T cells and HLA-DR+ NK cells could not predict active disease after NTZ suspension.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Células Matadoras Naturais
/
Natalizumab
/
Inflamação
/
Esclerose Múltipla
Tipo de estudo:
Prognostic_studies
/
Risk_factors_studies
Limite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article